ClinicalTrials.gg
RecruitingNCT04636775Updated Dec 11, 2023

Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC)

An observational study in NSCLC Stage IV and NSCLC, Recurrent, sponsored by Jun Zhang, MD, PhD. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Jun Zhang, MD, PhD · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jul 2020; still recruiting 6 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
46
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 521 open to participants now, 895 under way, 141 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Planned enrollment
157th of 246
46 · median 100
Started
2020
with 154 others
Observational
246 of 3,374
49 open now
Primary completion
2024-08
later than 76 of 893 live
Registered
2,431st of 3,374
by date

Among the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 157th largest by planned enrollment of the 246 observational ones that give a count, is one of 155 that started in 2020, is one of 246 observational ones, reaches primary completion later than 76 of the 893 other live ones, and was the 2,431st registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

521 of the 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

516 more — sign in →

All 521 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,374 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer, immunotherapy naive participants can predict the effectiveness of immunotherapy treatment as well as determine ahead of time adverse events and their severity. In addition, the investigator will look into microbiome changing modifiers.

03

Conditions studied

  • NSCLC Stage IV
  • NSCLC, Recurrent

Keywords

  • Advanced NSCLC
  • Metastatic NSCLC
  • Recurrent NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Immunotherapy naïve metastatic/advanced/recurrent NSCLC patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have tumor tissue -proven to be NSCLC
  • Must have a target lesion to evaluate treatment response
  • Immunotherapy naïve /advanced/recurrent NSCLC patients
  • Will receive single agent /PD-L1 therapy (e.g. pembrolizumab, nivolumab, atezolizumab, avelumab or durvalumab, etc.). Patients can be on other interventional trial if they will be receiving single agent anti-PD-1/PD-L1

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any forms of cancer immunotherapy
  • Not competent to make medical decision, noncommunicative or noncompliant per treating physician's judgement
  • Not English-speaking
  • Patients that are pregnant
  • Prisoners
  • Students and employees
  • Psychiatric illness/social situations that would limit compliance with study requirements
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
46 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Immunotherapy naïve NSCLC patients

    Microbiome in immunotherapy naïve NSCLC patients receiving PD-1/L1 blockade

    Diagnostic Test: Microbiome

Interventions

  • Diagnostic testMicrobiome

    Nasal and buccal swabs, and stool sample, as well as the extracted DNAs

06

What researchers measure

Primary outcomes

  1. Microbiome difference between patients with and without AEs>=grade 3

    Adverse events (AEs) will be graded per the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Microbiome difference between responders vs. nonresponders

    Treatment response will be evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1

    Time frame: Through study completion, an average of 1 year

  2. Correlation of microbiome to tumor tissue PD-L1 expression

    PD-L1 expression is per standard of care using IHC

    Time frame: Through study completion, an average of 1 year

  3. Correlation of microbiome to diet

    Customized Diet Survey

    Time frame: Through study completion, an average of 1 year

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Swami U, Zakharia Y, Zhang J. Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together. J Immunother. 2018 Oct;41(8):359-360. doi: 10.1097/CJI.0000000000000232. PubMed 29781826 ↗
  • Strouse C, Mangalam A, Zhang J. Bugs in the system: bringing the human microbiome to bear in cancer immunotherapy. Gut Microbes. 2019;10(2):109-112. doi: 10.1080/19490976.2018.1511665. Epub 2018 Sep 5. PubMed 30183502 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Aug 2024, 49 months after the start.

Of 358 non-industry observational studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 126. This study's planned 49 months is below that.

Counting every sponsor, half of 500 studies reached it within 55 months; a quarter within 35 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2020
First posted
Nov 19, 2020
StartActual
Jul 29, 2020
Primary completionEst.
Aug 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04636775
Lead sponsor
Jun Zhang, MD, PhD
Responsible party
Jun Zhang, MD, PhD (Associate Professor; Principal Investigator, University of Kansas Medical Center) — Sponsor-investigator
First posted
Nov 19, 2020
Start date
Jul 29, 2020
Primary completion
Aug 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Dec 11, 2023

Study contacts

KUCC Navigation
Contact
kucc_Navigation@kumc.edu
9135883671
Jun Zhang, MD, PhD
principal investigator · The University of Kansas Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion